Souhaitez-vous accéder aux communiqués récents ?

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Pasithea opens EU trial sites for PAS-004, doses Cohort 4, and plans interim safety data in Q1 2025.

Pasithea Tx' PAS-004 Phase 1 trial advances to a 15mg dose after no toxicities or rash observed, highlighting its safety and differentiated profile.

Pasithea Therapeutics' PAS-004 shows positive Phase 1 data: well-tolerated, no toxicities, promising efficacy in NF1 and MAPK-driven cancers.

Biomed Valley Discoveries today announced that the first patient has been dosed in a Phase 2 study of ulixertinib for the treatment of histiocytosis.

Pasithea Therapeutics completes enrollment and initial dosing of Cohort 2 in its Phase 1 trial of PAS-004, with interim safety data expected in Q3 2024.

Pasithea to present preclinical data at ASCO 2024 showing PAS-004 superior inhibition of NRAS cancer cells and xenograft tumors compared to current MEKi's

QTX3034, G12D-preferring multi-KRAS inhibitor, IND received clearance by US FDA to begin Phase 1 study; planned for 1Q24; and other pipeline updates

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

The combination of QTX3034, a multi-KRAS inhibitor, and EGFR inhibitors demonstrated potent, synergistic anti-tumor activity in preclinical studies.